A systematic review and meta-analysis indicated that weight loss seemed to be associated with significant improvements in biomarkers of liver disease such as ALT, and AST in subjects with NAFLD in the short term.[28] In this study ALT and AST levels reduced significantly at the end of the study (P < .001). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.